001     156841
005     20240229123118.0
024 7 _ |a 10.1038/s41416-020-0900-0
|2 doi
024 7 _ |a pmid:32555365
|2 pmid
024 7 _ |a 0007-0920
|2 ISSN
024 7 _ |a 1532-1827
|2 ISSN
024 7 _ |a altmetric:84216307
|2 altmetric
037 _ _ |a DKFZ-2020-01158
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Martins, Filipe Correia
|b 0
245 _ _ |a Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
260 _ _ |a Edinburgh
|c 2020
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1602764192_3285
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Sep;123(5):793-802
520 _ _ |a PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker in epithelial ovarian cancer in a large population-based study.Tumours from 5400 patients from a multicentre observational, prospective cohort study of the Ovarian Tumour Tissue Analysis Consortium were used to evaluate associations between immunohistochemical PTEN patterns and overall survival time, age, stage, grade, residual tumour, CD8+ tumour-infiltrating lymphocytes (TIL) counts, expression of oestrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR) by means of Cox proportional hazard models and generalised Cochran-Mantel-Haenszel tests.Downregulation of cytoplasmic PTEN expression was most frequent in ENOC (most frequently in younger patients; p value = 0.0001) and CCOC and was associated with longer overall survival in HGSOC (hazard ratio: 0.78, 95% CI: 0.65-0.94, p value = 0.022). PTEN expression was associated with ER, PR and AR expression (p values: 0.0008, 0.062 and 0.0002, respectively) in HGSOC and with lower CD8 counts in CCOC (p value < 0.0001). Heterogeneous expression of PTEN was more prevalent in advanced HGSOC (p value = 0.019) and associated with higher CD8 counts (p value = 0.0016).PTEN loss is a frequent driver in ovarian carcinoma associating distinctly with expression of hormonal receptors and CD8+ TIL counts in HGSOC and CCOC histotypes.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Couturier, Dominique-Laurent
|b 1
700 1 _ |a Paterson, Anna
|b 2
700 1 _ |a Karnezis, Anthony N
|b 3
700 1 _ |a Chow, Christine
|b 4
700 1 _ |a Nazeran, Tayyebeh M
|b 5
700 1 _ |a Odunsi, Adekunle
|b 6
700 1 _ |a Gentry-Maharaj, Aleksandra
|b 7
700 1 _ |a Vrvilo, Aleksandra
|b 8
700 1 _ |a Hein, Alexander
|b 9
700 1 _ |a Talhouk, Aline
|b 10
700 1 _ |a Osorio, Ana
|b 11
700 1 _ |a Hartkopf, Andreas D
|b 12
700 1 _ |a Brooks-Wilson, Angela
|b 13
700 1 _ |a DeFazio, Anna
|b 14
700 1 _ |a Fischer, Anna
|b 15
700 1 _ |a Hartmann, Arndt
|b 16
700 1 _ |a Hernandez, Brenda Y
|b 17
700 1 _ |a McCauley, Bryan M
|b 18
700 1 _ |a Karpinskyj, Chloe
|b 19
700 1 _ |a de Sousa, Christiani B
|b 20
700 1 _ |a Høgdall, Claus
|b 21
700 1 _ |a Tiezzi, Daniel G
|b 22
700 1 _ |a Herpel, Esther
|b 23
700 1 _ |a Taran, Florin Andrei
|b 24
700 1 _ |a Modugno, Francesmary
|b 25
700 1 _ |a Keeney, Gary
|b 26
700 1 _ |a Nelson, Gregg
|b 27
700 1 _ |a Steed, Helen
|b 28
700 1 _ |a Song, Honglin
|b 29
700 1 _ |a Luk, Hugh
|b 30
700 1 _ |a Benitez, Javier
|b 31
700 1 _ |a Alsop, Jennifer
|b 32
700 1 _ |a Koziak, Jennifer M
|b 33
700 1 _ |a Lester, Jenny
|b 34
700 1 _ |a Rothstein, Joseph H
|b 35
700 1 _ |a de Andrade, Jurandyr M
|b 36
700 1 _ |a Lundvall, Lene
|b 37
700 1 _ |a Paz-Ares, Luis
|b 38
700 1 _ |a Robles-Díaz, Luis
|b 39
700 1 _ |a Wilkens, Lynne R
|b 40
700 1 _ |a Garcia, Maria J
|b 41
700 1 _ |a Intermaggio, Maria P
|b 42
700 1 _ |a Alcaraz, Marie-Lyne
|b 43
700 1 _ |a Brett, Mary A
|b 44
700 1 _ |a Beckmann, Matthias W
|b 45
700 1 _ |a Jimenez-Linan, Mercedes
|b 46
700 1 _ |a Anglesio, Michael
|b 47
700 1 _ |a Carney, Michael E
|b 48
700 1 _ |a Schneider, Michael
|b 49
700 1 _ |a Traficante, Nadia
|b 50
700 1 _ |a Pejovic, Nadja
|b 51
700 1 _ |a Singh, Naveena
|b 52
700 1 _ |a Le, Nhu
|b 53
700 1 _ |a Sinn, Peter
|b 54
700 1 _ |a Ghatage, Prafull
|b 55
700 1 _ |a Erber, Ramona
|b 56
700 1 _ |a Edwards, Robert
|b 57
700 1 _ |a Vierkant, Robert
|b 58
700 1 _ |a Ness, Roberta B
|b 59
700 1 _ |a Leung, Samuel
|b 60
700 1 _ |a Orsulic, Sandra
|b 61
700 1 _ |a Brucker, Sara Y
|b 62
700 1 _ |a Kaufmann, Scott H
|b 63
700 1 _ |a Fereday, Sian
|b 64
700 1 _ |a Gayther, Simon
|b 65
700 1 _ |a Winham, Stacey J
|b 66
700 1 _ |a Kommoss, Stefan
|b 67
700 1 _ |a Pejovic, Tanja
|b 68
700 1 _ |a Longacre, Teri A
|b 69
700 1 _ |a McGuire, Valerie
|b 70
700 1 _ |a Rhenius, Valerie
|b 71
700 1 _ |a Sieh, Weiva
|b 72
700 1 _ |a Shvetsov, Yurii B
|b 73
700 1 _ |a Whittemore, Alice S
|b 74
700 1 _ |a Staebler, Annette
|b 75
700 1 _ |a Karlan, Beth Y
|b 76
700 1 _ |a Rodriguez-Antona, Cristina
|b 77
700 1 _ |a Bowtell, David D
|b 78
700 1 _ |a Goode, Ellen L
|b 79
700 1 _ |a Høgdall, Estrid
|b 80
700 1 _ |a Candido Dos Reis, Francisco J
|0 0000-0001-5758-5917
|b 81
700 1 _ |a Gronwald, Jacek
|b 82
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 83
|u dkfz
700 1 _ |a Moysich, Kirsten B
|b 84
700 1 _ |a Kelemen, Linda E
|b 85
700 1 _ |a Cook, Linda S
|b 86
700 1 _ |a Goodman, Marc T
|b 87
700 1 _ |a Fasching, Peter A
|b 88
700 1 _ |a Crawford, Robin
|b 89
700 1 _ |a Deen, Suha
|b 90
700 1 _ |a Menon, Usha
|b 91
700 1 _ |a Huntsman, David G
|b 92
700 1 _ |a Köbel, Martin
|b 93
700 1 _ |a Ramus, Susan J
|b 94
700 1 _ |a Pharoah, Paul D P
|b 95
700 1 _ |a Brenton, James D
|0 0000-0002-5738-6683
|b 96
773 _ _ |a 10.1038/s41416-020-0900-0
|0 PERI:(DE-600)2002452-6
|n 5
|p 793-802
|t British journal of cancer
|v 123
|y 2020
|x 1532-1827
909 C O |o oai:inrepo02.dkfz.de:156841
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 83
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-01-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J CANCER : 2018
|d 2020-01-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-01-12
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-01-12
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BRIT J CANCER : 2018
|d 2020-01-12
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21